Evidence map›Paper›PMID 40842910›Full record

ReviewInternational journal of preventive medicine2025

Local Guidelines Regarding the Therapeutic and Diagnostic Management of Silent Crohn's Patients.

Mohammad Rezaeisadrabadi, Babak Tamizifar, Peyman Adibi

Abstract readReview
In one paragraph

Review in International journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammad RezaeisadrabadiGastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Babak TamizifarGastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Peyman AdibiGastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease is a chronic and progressive inflammatory disease of the gastrointestinal tract; whose symptoms recur and subside. This disease mainly affects the ileum and terminal colon and usually causes segmental, asymmetric, and transmural inflammation. Its clinical symptoms are variable, including diarrhea, abdominal pain, rectal bleeding, weight loss, and skin lesions. Due to the unknown causes of this disease, it is difficult to diagnose and manage it, especially in cases of silent Crohn's disease that does not have clear symptoms, and this has made the diagnosis of silent Crohn's a serious challenge for specialists. Unfortunately, today there is no specific guideline for the diagnosis and management of silent Crohn's disease, and the purpose of this research is to provide such a guideline. Two separate approaches were adopted: firstly, the evaluation of international articles (researchers' point of view) and the second part, the evaluation of the opinions of Iranian specialists active in the field of diagnosis and treatment of Crohn's patients (experts' point of view). in terms of Therefore, the opinions and discussions raised in international articles regarding diagnostic methods, clinical indicators, alternative methods in diagnosis, treatment methods, methods of monitoring treatment, and follow-up are reviewed, summarized, and compared with the opinions and performance of experts. Internally placed. According to experts' opinions, questions were designed based on scenarios of patients with special conditions. Then, the opinions of the country's most prominent internal medicine and gastroenterology specialists were recorded in person or by phone. Finally, the opinions were summarized and a proposed recommendation was created for the diagnosis of silent Crohn's disease. Mainly for the initial diagnosis of silent Crohn's depending on the condition of the disease, the diagnosis of aphthous lesions similar to Crohn's, in patients with high CRP and other inflammatory indicators or fecal calprotectin, the diagnostic recommendations were based on colonoscopy-based methods. Endoscopy (capsule) and especially ileocolonoscopy, fecal calprotectin assay, but no diagnosis is superior to histopathological findings. For treatment, steroid immunosuppressive drugs, mesalazine, budesonide, azathioprine, and sometimes surgery are useful. In cases where the intensity of the lesions is low, the use of non-steroidal anti-inflammatory drugs and acetylsalicylate recommended. However, there is often no need for therapeutic intervention and the lesions may have resolved spontaneously during follow-up. For the diagnosis of silent Crohn's disease, our proposed guideline can be of great help to physicians, as the most available tools are identified in diagnosis, disease monitoring, treatment, and follow-up. We recommend that the effectiveness of this guideline in the diagnosis and treatment of silent Crohn's disease be investigated by other researchers.

Indexed as

Anti-inflammatory drugscalprotectinileocolonoscopyinflammatory bowel diseasesilent Crohn’s disease

Identifiers

PMID40842910
PMCPMC12367252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.